Inflation
Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs
Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.
Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change
Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts
Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024
Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform
Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.
Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government
Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory